GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Additional Paid-In Capital

Grifols (XMAD:GRF) Additional Paid-In Capital : €911 Mil(As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Grifols Additional Paid-In Capital?


Grifols's quarterly additional paid-in capital stayed the same from Jun. 2023 (€911 Mil) to Sep. 2023 (€911 Mil) and stayed the same from Sep. 2023 (€911 Mil) to Dec. 2023 (€911 Mil).

Grifols's annual additional paid-in capital stayed the same from Dec. 2021 (€911 Mil) to Dec. 2022 (€911 Mil) and stayed the same from Dec. 2022 (€911 Mil) to Dec. 2023 (€911 Mil).

Grifols Additional Paid-In Capital Historical Data

The historical data trend for Grifols's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Additional Paid-In Capital Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 910.73 910.73 910.73 910.73 910.73

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 910.73 910.73 910.73 910.73

Grifols Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Grifols Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Grifols's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (XMAD:GRF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (XMAD:GRF) » Definitions » Additional Paid-In Capital
Comparable Companies
XMAD:AEDAS XMAD:NEA XMAD:BKT XMAD:ALB XMAD:NTH XMAD:AZK XMAD:BST XMAD:TRE XMAD:ACX XMAD:ELE LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN XPAR:SAN
Traded in Other Exchanges
GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain OZTA:Germany
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Website
https://www.grifols.com
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.